Ferring Pharmaceuticals US recently announced that it is recalling four types of nasal sprays containing desmopressin due to superpotency:
- DDVAP Nasal Spray 10 mcg/0.1mL, which is used as an anti-diuretic replacement therapy in the management of central cranial diabetes insipidus and after head trauma or surgery in the pituitary region
- Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, which is used for similar purposes.
- Stimate Nasal Spray 1.5 mg/mL, which is used to treat patients with hemophilia A with Factor VII coagulant activity levels greater than 5% and patients with mild to moderate classic von Willebrand’s disease (Type 1) with Factor VIII levels greater than 5%.
According to a release by the U.S. Food and Drug Administration on August 5, 2020, the nasal sprays are being recalled because they contain too much of their active ingredient, desmopressin. People who take medications with excessive amounts of desmopressin may experience abnormally low levels of sodium in their blood, a condition called hyponatremia. This condition can result in seizure, coma, or death.
When it comes to both prescription and over-the-counter medications, dosage is extremely important. Patients who take drugs with too low of a dosage may not get therapeutic effects to treat their illnesses or diseases, while patients who take drugs with dosages that are too high may experience more severe side effects and complications.
It’s extremely important for pharmaceutical companies to ensure that their medications are shipped and properly labeled and contain the right dosages of active ingredients. It’s also vital that doctors and pharmacists ensure patients get the right dosages for their age, body weight, and particular conditions.
If you or someone you love was harmed by a medication that was improperly dosed or labeled, we want to speak with you. Contact the drug injury lawyers at Ferrer Poirot Feller Daniel today for a free consultation.